Clinical characteristics of SARS-CoV-2 infection in patients with chronic hepatitis B during interferon antiviral therapy

EASL Recognition Awardee 2013: Professor Yun-Fan Liaw

Management of patients with hepatitis B virus-induced cirrhosis

Chapter 1: Prevention

Chronic Hepatitis B: A Critical Appraisal of Current Approaches to Therapy

Objective To study the relationship between X region mutations of chronic hepatitis B and curative effect of pegylated interferon α-2a. Methods Patients with chronic hepatitis B (e antigen positive) were enrolled, treated with pegylated interferon α-2a. Enrolled patients serum specimens of base line and after 12 weeks treatment were collected. After 12 weeks, depending on the HBV DNA falling degree, patients were divided into three groups: DNA response group, DNA partial response group, DNA non-response group. Then HBV full genome in the serum (baseline) was amplificated, cloned and sequenced. Analysis the relationship of X region mutations and pegylated interferon α-2a treatment-related effect by logistic regression.P<0.05 was considered statistically significant. Results 29 patients data was analyzed, which including T patients from DNA response group, 9 palients from DNA partial response group and 13 palients from DNA non-response group. At baseline, the difference of ALT was statistically significant(χ2=10.732, P=0.005). Among three groups, the differences of age, gender, HBVDNA, HBsAg and HBeAg, HBeAb were not statistically significant. Total of 306 sequences were obtained. The number of X region nucleotide mutation sites, according to statistically significant and clinical response, was 16.Multivariate logistic regression analysis showed ntG1386A, ntG1437A and ntG1515A were in favor of interferon antiviral therapy; but ntC1383A, ntT1425C and ntG1512A are risk factors unfavorable for interferon antiviral therapy. Amino acid level analysis found that V5M, G22S and D48N were favorable factors for interferon treatment, but V30L and A47T were negative factors for interferon treatment. Conclusions X region mutations may be correlated with therapeutic effect of pegylated interferon α-2a. Key words: Hepatitis B, Chronic; Polyethylene glycols; Interferon alfa-2a; Muation

Is there sufficient evidence to recommend antiviral therapy in hepatitis C?

Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data

Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

Serum markers detect the presence of liver fibrosis: A cohort study

Antiviral T-cell responses and therapy in chronic hepatitis B

Are viral or host factors predictive of response to interferon–ribavirin in transplant patients with hepatitis C?

Fibrosis in chronic liver diseases: diagnosis and management

Toward prevention of hepatocellular carcinoma developing in chronic hepatitis C

Hepatitis in haemophilia.